Skip to content

Celcuity CELC Stock-Based Comp

Stock-Based Comp at other companies

Eli Lilly logo
Eli LillyLLY
$161M+4.5%
Gilead Sciences logo
Gilead SciencesGILD
$218M+4.3%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$33.24M+28.4%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$10.54M-45.5%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$16.91M+68.9%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$10.8M+48.8%

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.28B+1,370%
Enterprise value$4.27B+1,086%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's stock-based comp?
Celcuity (CELC) reported stock-based comp of $5.33M in Q1 2026.
How has Celcuity's stock-based comp changed year-over-year?
Celcuity's stock-based comp increased by 117.9% year-over-year, from $2.44M to $5.33M.
What is the long-term trend for Celcuity's stock-based comp?
Over 4 years (2021 to 2025), Celcuity's stock-based comp has grown at a 69.2% compound annual growth rate (CAGR), from $2.61M to $21.38M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.